Failure to follow up on test results is one of the most frequent issues identified in lawsuits brought against physicians and health care organizations. Read this presentation for guidance on how to create effective follow-up strategies.
How to Increase Telehealth in Diabetes Care (June 2019 - DData Exchange)Aaron Neinstein
Dr. Aaron Neinstein, Endocrinology Professor at UCSF, describes the use of diabetes technology and telehealth for diabetes care, barriers that are being overcome, and barriers yet to be. Presented at the June 2019 DiabetesMine DData Exchange.
Meaningful Use encompasses multiple stages, each with specific timeline and measure requirements that continue to be a moving target. This can be a confusing process, sending providers in a tailspin in their attempts to stay current. This webinar focuses on the overall details of Meaningful Use and provides a nice outline of all of its details.
Failure to follow up on test results is one of the most frequent issues identified in lawsuits brought against physicians and health care organizations. Read this presentation for guidance on how to create effective follow-up strategies.
How to Increase Telehealth in Diabetes Care (June 2019 - DData Exchange)Aaron Neinstein
Dr. Aaron Neinstein, Endocrinology Professor at UCSF, describes the use of diabetes technology and telehealth for diabetes care, barriers that are being overcome, and barriers yet to be. Presented at the June 2019 DiabetesMine DData Exchange.
Meaningful Use encompasses multiple stages, each with specific timeline and measure requirements that continue to be a moving target. This can be a confusing process, sending providers in a tailspin in their attempts to stay current. This webinar focuses on the overall details of Meaningful Use and provides a nice outline of all of its details.
Clinical Data Quality in Mozambique: A Comparative ExerciseJSI
Presentation for the American Public Health Association & Expo in Atlanta, GA. November 2017:
Ensuring that quality data are collected and reported to the Ministry of Health (MOH) is a priority in Mozambique as it is the foundation for the provision of quality health services. Since 2014, the Strategic Information Project in Mozambique (M-SIP) has provided technical assistance to MOH to conduct annual rounds of data quality assessments (DQA) in each province. Seven indicators were selected as part of the national DQA strategy. Each DQA had a quantitative and a system assessment component. The quantitative component includes tracing and verification of reported data, where recounted data is compared to data reported at three levels: health facility (HF), district, and province. M-SIP conducted all DQAs using the same methodology making the results comparable. After three consecutive national rounds, there is a clear trend of improvement, despite deviations remaining high. The regular, reinforcing nature of this activity and consistency of HF recommendations has had a positive impact on the data quality and results of the assessments. For example, the overall national deviation of the “patients active in ART” indicator decreased from 37% to 22% over the three-year period. The successful implementation of the DQA activity, as well as its unique, inclusive approach to promoting MOH ownership, has resulted in MOH recognition—at all levels—that DQA activities are crucial to future success. The M-SIP and MOH teams are now developing a more methodological approach to MOH staff empowerment, enabling fully independent MOH implementation of this activity while continuing to improve the quality of data.
A short presentation outlining risk management resources and recommendations for physicians as they continue to practice medicine during COVID-19. Topics include encouraging social distancing and screening patients.
iHT² Health IT Summit San Francisco “Connecting the Data: Improving Outcomes and Quality with Clinical and Claims Data”
There is a fundamental need in today’s healthcare system for the two largest constituents—payers and providers—to work together in alignment. Changing the thinking and actions to shift the dynamic of how payors and providers work and interact with each other is no small task. This session will address the challenges and opportunities for payors and providers to work together. Panelists will discuss examples of collaboration and lessons learned.
Learning Objectives:
∙ Assess the structure of provider-payor collaborations reducing cost and improving outcomes
∙ Identify methods to combine clinical and claims data to glean insight
∙ Define clinical, economic and administrative opportunities for alignment
Moderator: Jay Srini, Chief Strategist, SCS Ventures, Adjunct Faculty Assistant Professor, University of Pittsburgh, Senior Fellow and Innovation Chair, iHT² Advisory Board Member
Betsy Thompson, MD, DrPH, Chief Medical Officer, Region IX, Centers for Medicare and Medicaid Services
Brett Johnson, Associate Director, Medical and Regulatory Policy, California Medical Association (CMA)
Clinical Data Quality in Mozambique: A Comparative ExerciseJSI
Presentation for the American Public Health Association & Expo in Atlanta, GA. November 2017:
Ensuring that quality data are collected and reported to the Ministry of Health (MOH) is a priority in Mozambique as it is the foundation for the provision of quality health services. Since 2014, the Strategic Information Project in Mozambique (M-SIP) has provided technical assistance to MOH to conduct annual rounds of data quality assessments (DQA) in each province. Seven indicators were selected as part of the national DQA strategy. Each DQA had a quantitative and a system assessment component. The quantitative component includes tracing and verification of reported data, where recounted data is compared to data reported at three levels: health facility (HF), district, and province. M-SIP conducted all DQAs using the same methodology making the results comparable. After three consecutive national rounds, there is a clear trend of improvement, despite deviations remaining high. The regular, reinforcing nature of this activity and consistency of HF recommendations has had a positive impact on the data quality and results of the assessments. For example, the overall national deviation of the “patients active in ART” indicator decreased from 37% to 22% over the three-year period. The successful implementation of the DQA activity, as well as its unique, inclusive approach to promoting MOH ownership, has resulted in MOH recognition—at all levels—that DQA activities are crucial to future success. The M-SIP and MOH teams are now developing a more methodological approach to MOH staff empowerment, enabling fully independent MOH implementation of this activity while continuing to improve the quality of data.
A short presentation outlining risk management resources and recommendations for physicians as they continue to practice medicine during COVID-19. Topics include encouraging social distancing and screening patients.
iHT² Health IT Summit San Francisco “Connecting the Data: Improving Outcomes and Quality with Clinical and Claims Data”
There is a fundamental need in today’s healthcare system for the two largest constituents—payers and providers—to work together in alignment. Changing the thinking and actions to shift the dynamic of how payors and providers work and interact with each other is no small task. This session will address the challenges and opportunities for payors and providers to work together. Panelists will discuss examples of collaboration and lessons learned.
Learning Objectives:
∙ Assess the structure of provider-payor collaborations reducing cost and improving outcomes
∙ Identify methods to combine clinical and claims data to glean insight
∙ Define clinical, economic and administrative opportunities for alignment
Moderator: Jay Srini, Chief Strategist, SCS Ventures, Adjunct Faculty Assistant Professor, University of Pittsburgh, Senior Fellow and Innovation Chair, iHT² Advisory Board Member
Betsy Thompson, MD, DrPH, Chief Medical Officer, Region IX, Centers for Medicare and Medicaid Services
Brett Johnson, Associate Director, Medical and Regulatory Policy, California Medical Association (CMA)
Go deeper with athenahealth specialists to discover all that you need to know and some things you may not know about Meaningful Use Stage 2 and the newest government updates.
Meaningful Use Stage 2 and Health Information Exchange (HIE)MassEHealth
Transformational intent of Meaningful Use (MU) and the increased trend toward interoperability in MU Stage 2 (MU2); MU2 objectives with an HIE component and their MU2 measures; Approaches to achieving the transitions of care; Available public health registries and their current status and submission pathway; How to find a trading partner and best practices to engaging
Stage 2 Meaningful Use brings more stringent requirements for the Stage 1 measures, a host of new measures, and a greater focus on clinical quality measures. In this instructive session, our expert faculty members review:
*The requirements and timeline for implementation of Stage 2 Meaningful Use
*The top five questions you need to ask to determine if your organization is ready for Stage 2
*The steps you can take to prepare your organization to successfully meet the Stage 2 requirements and get the most out of your EHR system
Due to popular demand, the Comprehensive Primary Care Plus (CPC+) team hosted a repeat of the webinar that was originally held on Thursday, April 21, 2016. During this webinar Model team members provided an overview of the model specifically for health IT vendors.
- - -
CMS Innovation Center
http://innovation.cms.gov
We accept comments in the spirit of our comment policy:
http://newmedia.hhs.gov/standards/comment_policy.html
CMS Privacy Policy
http://cms.gov/About-CMS/Agency-Information/Aboutwebsite/Privacy-Policy.html
Meaningful Use in 2015: 6 things to do before the year’s endCureMD
What's in these slides?
1 ) Implementation timeline and requirements.
2 ) What measures have made it to the final list and how to achieve them?
3 ) A checklist of things to do before the year’s end.
4 ) What to expect from stage 3?
Keynote Presentation "Meaningful Use Stage 2 and Meaningful Use Audit Insight"
Think far beyond just threshold increases. The differences between Meaningful Use (MU) Stage 1 and Stage 2, including the 2014 Clinical Quality Measures, are technically and clinically challenging. And just when you thought you could safely look at Stage 1 in the rearview mirror, here come the audits! I will highlight the Stage 1 and Stage 2 differences and talk about the challenges they have initiated at Tenet. I will touch on the impact of Quality measures and will also provide you with insight into the basics of MU Audits and will take you through the actual audit experience at Tenet.
Learning Objectives:
∙ Review the program and measure changes from Stage 1 to Stage 2 and how the changes are being managed at Tenet
∙ Provide insight into the 2014 Clinical Quality Measures chosen by Tenet, the challenges posed, solutions that work and a little about the overall
impact of Quality measures
∙ Discuss Meaningful Use Audits, covering the basics as well as providing the benefit of the Tenet experience
Webinar - Telehealth: Bridging the Doctor-Patient DivideCareSkore
Do you risk negative outcomes due to poor patient engagement? Without technology, you can’t fully enlist patients to participate in their own care. This leads to rising no-show rates, medication non-adherence, and uninformed patient decisions, resulting in readmissions, lower MIPS scores, and lower reimbursements.
Similar to Andrea walrath mu stage 2 and beyond (20)
Michigan Health Information Network Shared Services MiHIN ADT Admit Discharge Transfer ONC Office of the National Coordinator for Health Information Technolgy HIT HIE
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
3. 3
Why Meaningful Use?
The Department of Health and Human Services
(HHS) envisions “an information rich, person-
centered, high performance health care system
where every health care provider has access to
longitudinal data on patients they treat to make
evidence-based decisions, coordinate care and
improve health outcomes.”
4. 4
Meaningful Use as the foundation
Meaningful use is using certified electronic health
record (EHR) technology to:
▲Improve quality, safety, efficiency, and reduce
health disparities
▲Engage patients and family
▲Improve care coordination, and population and
public health
▲Maintain privacy and security of patient health
information
9. 9
Meaningful Use: Stage 2 and Beyond
Stage 1:
Data Capture
and Sharing
Stage 2:
Advance
Clinical
Processes
Stage 3:
Improved
Outcomes
10. 10
Stage 2 and Beyond
Stage 1 Stage 2 Stage 3
Electronically capturing health
information in a standardized
format
More rigorous health
information exchange (HIE)
Improving quality, safety, and
efficiency, leading to improved
health outcomes
Using that information to track
key clinical conditions
Increased requirements for e-
prescribing and incorporating
lab results
Decision support for national
high-priority conditions
Communicating that
information for care
coordination processes
Electronic transmission of
patient care summaries across
multiple settings
Patient access to self-
management tools
Initiating the reporting of
clinical quality measures and
public health information
More patient-controlled data
Access to comprehensive
patient data through patient-
centered HIE
Using information to engage
patients and their families in
their care
Improving population health
12. 12
Stage 2: Transitions of Care
The Transition of Care objective includes 3
measures:
▲ Measure #1 requires the provision of
a summary of care record for more
than 50% of transitions of care and
referrals.
▲ Measure #2 requires that the
provision of a summary of care record
using electronic transmission through
CEHRT or eHealth Exchange
participant for more than 10% of
transitions of care and referrals
▲ Measure #3 requires at least one
summary care record electronically
transmitted to recipient with different
EHR vendor or to CMS test EHR
Stage 1Stage 2
Stage 2
Stage 2
13. 13
Stage 2: Lab Exchange
▲ Objective: Incorporate clinical lab
test results into CEHRT as structured
data
▲ Measure: More than 40% of all
clinical lab test results ordered by the
EP are incorporated in CEHRT as
structured data
▲ Measure: More than 55% of all
clinical lab test results ordered by the
EP are incorporated in CEHRT as
structured data
Stage 1 (Menu)Stage 2
Stage 1
Stage 2
14. 14
Stage 2: Patient Engagement
Provide patients the ability to
view online, download and
transmit their health information
Requirements for Patient Action:
▲More than 5% of patients must
send secure messages to their
EP
▲More than 5% of patients must
view, download, or transmit
their health information
15. 15
Stage 2: Public Health
Includes 4 Core and Menu Objectives for EPs:
▲ (Core) Immunization Registry: Successful
ongoing submission of electronic immunization
data from CEHRT to an immunization registry
or IIS for the entire EHR reporting period
▲ (Menu) Syndromic Surveillance: Successful
ongoing submission of electronic syndromic
surveillance data from CEHRT to a PHA for the
entire EHR reporting period
▲ (Menu) Cancer Registry: Successful ongoing
submission of cancer case information from
CEHRT to a state cancer registry for the entire
EHR reporting period
▲ (Menu) Specialty Registry: Successful
ongoing submission of clinical and case
information from CEHRT to a specialty registry
for the entire EHR reporting period
Stage 1 (Menu)
Stage 1
Stage 2
Stage 2
Stage 2
Stage 2
16. 16
Most commonly deferred Stage 1 Menu
Objectives:
▲ Providing a summary of care to
patients at transitions to other
physicians or hospitals — 84%
▲ Using the EHR to send reminders to
specific groups of patients about
preventive care — 80%
▲ Sending information to public health
agencies or syndromic surveillance —
68%
▲ Being able to give patients electronic
access to their records — 66%
Stage 2: Preparation
Transitions of Care
Patient Engagement
Public Health
Patient Engagement
17. 17
Stage 2: Preparation
▲Stage 1
–Look ahead!
▲2014 CEHRT
–Required for all stages in 2014
–3-month reporting period
▲Health Information Exchange
–Connect!
